Literature DB >> 25909352

The clinical importance of lumbosacral transitional vertebra in patients with adolescent idiopathic scoliosis.

Choon Sung Lee1, Jung-Ki Ha, Dae Geun Kim, Chang Ju Hwang, Dong-Ho Lee, Jae Hwan Cho.   

Abstract

STUDY
DESIGN: Retrospective review of radiographs.
OBJECTIVE: The objective of this study was to (1) determine the prevalence of lumbosacral transitional vertebra (LSTV) with computed tomography (CT) and (2) correlate LSTV presence with lumbar disc degeneration at each level by magnetic resonance imaging. SUMMARY OF BACKGROUND DATA: LSTV is a frequently observed abnormality. Although its prevalence in patients with adolescent idiopathic scoliosis (AIS) has been shown, no studies have yet examined the clinical importance of LSTV in patients with AIS.
METHODS: This study included 385 consecutive patients who underwent surgery for AIS at a single center. Plain radiographs and CT scans were used to detect LSTV. Disc degeneration was analyzed at the L3-4, L4-5, and L5-S1 disc levels with magnetic resonance imaging. The difference in disc degeneration at each level by the presence of LSTV was also analyzed. The effect of lumbar curve type on the disc degeneration of each level was then determined. To minimize confounding factors, logistic regression analysis was performed.
RESULTS: The overall prevalence of LSTV in patients with AIS confirmed by CT scans was 12.2% (47/385). The proportion of grade II or more disc degeneration at the L4-5 level was higher in the LSTV(+) group than in the LSTV(-) group (29.8% vs.19.2%) although it was not statistically significant (P = 0.093). Large lumbar curves showed a positive correlation with disc degeneration at the L5-S1 level (P = 0.022).
CONCLUSION: The prevalence of LSTV in patients with AIS was 12.2%. A trend of early degeneration in L4-5 level discs was found in patients with AIS with LSTV although it was not statistically confirmed. Disc degeneration at the L5-S1 level is related to a large lumbar curve. If patients with AIS with large lumbar curves have LSTV, consideration should be given to stopping the distal fusion at L3 instead of L4. LEVEL OF EVIDENCE: 4.

Entities:  

Mesh:

Year:  2015        PMID: 25909352     DOI: 10.1097/BRS.0000000000000945

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  6 in total

Review 1.  A review of lumbosacral transitional vertebrae and associated vertebral numeration.

Authors:  Jayson Lian; Nicole Levine; Woojin Cho
Journal:  Eur Spine J       Date:  2018-03-21       Impact factor: 3.134

2.  Neuromuscular scoliosis in the presence of spina bifida occulta and a transitional lumbosacral vertebra: A case report.

Authors:  Eric Chun-Pu Chu
Journal:  Radiol Case Rep       Date:  2022-07-04

3.  Is it enough to stop distal fusion at L3 in adolescent idiopathic scoliosis with major thoracolumbar/lumbar curves?

Authors:  Choon Sung Lee; Jung-Ki Ha; Chang Ju Hwang; Dong-Ho Lee; Tae Hyung Kim; Jae Hwan Cho
Journal:  Eur Spine J       Date:  2016-01-13       Impact factor: 3.134

4.  The morphological relationship between lumbosacral transitional vertebrae and lumbosacral pedicle asymmetry.

Authors:  Teruaki Ono; Kiyoshi Tarukado; Osamu Tono; Katsumi Harimaya; Yuichiro Morishita; Yasuharu Nakashima; Toshio Doi
Journal:  Spine Surg Relat Res       Date:  2018-01-27

5.  Lumbosacral transitional vertebrae alter the distribution of lumbar mobility-Preliminary results of a radiographic evaluation.

Authors:  Luis Becker; Lukas Schönnagel; Tim Victor Mihalache; Henryk Haffer; Friederike Schömig; Hendrik Schmidt; Matthias Pumberger
Journal:  PLoS One       Date:  2022-09-29       Impact factor: 3.752

6.  Double Crush of L5 Spinal Nerve Root due to L4/5 Lateral Recess Stenosis and Bony Spur Formation of Lumbosacral Transitional Vertebra Pseudoarticulation: A Case Report and Review.

Authors:  Motoyuki Iwasaki; Masahiko Akiyama; Izumi Koyanagi; Yoshimasa Niiya; Tatsuo Ihara; Kiyohiro Houkin
Journal:  NMC Case Rep J       Date:  2017-09-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.